#United States #Princeton #Bracco Diagnostics #HeartSee™ #CAD Diagnosis

Major Update to HeartSee™ by Bracco Diagnostics

Bracco Diagnostics Inc., a subsidiary of Bracco Imaging S.p.A., has recently announced an impressive upgrade to their HeartSee™ software. This advanced diagnostic tool plays a vital role in assessing myocardial blood flow (MBF) through cardiac positron emission tomography (PET) imaging. Launched this March, the new version 4.0 reflects Bracco's commitment to improving the diagnosis and treatment of coronary artery disease (CAD).

Key Innovations in HeartSee™

The most notable enhancements focus on usability, accessibility, and data security. The upgraded software introduces new diagnostic capabilities, such as measuring subendocardial ischemia. This feature provides critical insights when other imaging modalities fail to capture the patient’s symptoms.

Another cutting-edge addition, named relative stress flow, enables an indirect assessment of subendocardial border zones where Coronary Flow Capacity (CFC) is slightly diminished, helping doctors better interpret complex cardiac conditions. Additionally, the incorporation of ejection fraction data within HeartSee™ makes it a comprehensive solution for cardiac assessments, consolidating essential information in one interface.

Improved Accessibility

To further democratize access to this advanced technology, Bracco is providing dedicated field support, conducting extensive training for healthcare professionals, and ensuring compatibility with Windows 10 and 11 operating systems. This seamless integration allows a diverse range of clinicians to utilize HeartSee™, enhancing patient care by providing easy access to important diagnostic tools.

Dr. Sergey Kachur, a recognized expert in nuclear cardiology, emphasized the significant role HeartSee™ has played since its introduction in 2018. He noted, “By accurately identifying suitable candidates for intervention, HeartSee™ has markedly improved treatment outcomes and minimized the necessity for invasive procedures, thus positively impacting patient care.”

The Importance of MBF and CFC Data

The relevance of MBF and CFR (Coronary Flow Reserve) data in managing CAD has been increasingly acknowledged in the cardiology community. HeartSee™ not only provides absolute measurements of MBF and CFR but also facilitates the evaluation of regional cardiac defects and calculating the CFC, offering comprehensive insights into patient heart health.

As Dr. James Feldman from Memorial Katy Cardiology Associates pointed out, HeartSee™ has become indispensable in their clinic. “Over time, we can't envision analyzing studies without HeartSee™ due to the extensive data it supplies. It’s an invaluable resource for our practice.”

Safety and Usage Guidelines

HeartSee™ is specifically designed for trained healthcare professionals who practice in nuclear medicine, cardiology, or possess specialized training in nuclear imaging. While heart physicians draw interpretations from PET images, the software serves to quantify the extent of coronary conditions, aiding in clinical decision-making.

In summary, the launch of the upgraded HeartSee™ software signifies a critical evolution in Bracco Diagnostics’ ongoing mission to bolster coronary artery disease diagnostics. With its enhanced features, the software aims to support healthcare providers in making informed decisions that lead to improved patient outcomes, setting a new standard in cardiac care.

For further details on Bracco Diagnostics and its innovative product offerings, please visit Bracco Imaging.